U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487740) titled 'A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants' on March 17.

Brief Summary: The primary purpose of this study is to evaluate the effect of a high-fat, high-calorie meal on the relative bioavailability of NAL ER following single oral doses.

Study Start Date: Feb. 27

Study Type: INTERVENTIONAL

Condition: Healthy Participants

Intervention: DRUG: NAL ER

Oral tablets

Recruitment Status: RECRUITING

Sponsor: Trevi Therapeutics

Published by HT Digital Content Services with permission from Health Daily Digest....